news

December 4, 2023

One of the great challenges of scientific and technological progress is that occasionally our intent to benefit human health can negatively impact our planet's health. Modern medicines are made through chemical processes, medical devices are made of plastic and polymerized molecules, materials needed to facilitate hygiene and sanitation are single use and disposable, and a significant amount of energy is consumed ...

press release

November 11, 2023

– Zilebesiran Met Primary Endpoint Demonstrating Up to 16.7 mmHg Placebo Adjusted Reduction of 24 Hour Mean Systolic Blood Pressure at Three Months of Treatment – – Study Met Key Secondary Endpoints Showing Consistent and Sustained Reductions of Systolic Blood Pressure and Durable Tonic Blood Pressure Control Through Month 6 – – Data Support Quarterly or Biannual Dosing – – Zilebesiran ...

press release

November 2, 2023

− Achieved Third Quarter 2023 Global Net Product Revenues of $313 Million, Representing 35% Year Over Year Growth Compared to Q3 2022 – − Received Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis – − Company Remains On Track to Report Topline Results from HELIOS B Phase ...

press release

September 7, 2023

- Zilebesiran Met Primary Endpoint Demonstrating Greater than 15 mmHg Reduction of Systolic Blood Pressure at Three Months of Treatment Compared to Placebo at Two Highest Single Doses Evaluated Study Met Key Secondary Endpoints Showing Consistent and Sustained Reductions of Systolic Blood Pressure at Six Months, Supporting Quarterly or Biannual Dosing Zilebesiran Demonstrated an Encouraging Safety and Tolerability Profile in Adult ...

press release

September 5, 2023

New study published in the BMJ Open calls for major shift in the management of hATTR amyloidosis CAMBRIDGE, Mass. – [BUSINESS WIRE] – September 06, 2023 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the first ever recommendations for patient and family centred holistic care for people living with hereditary transthyretin mediated amyloidosis, also known as ...

press release

August 3, 2023

− Achieved Second Quarter 2023 Global Net Product Revenues of $306 Million, Representing 43% Year Over Year Growth Compared to Q2 2022 – −Submitted 18 Month APOLLO B Data to the U.S. Food and Drug Administration as Amendment to Supplemental New Drug Application for Patisiran – −Presented Updated Positive Interim Results from Phase 1 Study of ALN APP in Patients with ...

press release

July 24, 2023

– Partnership Combines Alnylam’s Leadership in RNAi Therapeutics with Roche’s Proven Track Record of Successfully Developing and Launching Innovative Medicines Worldwide – – Zilebesiran Represents a Potentially Transformative Approach to Reducing CV Morbidity and Mortality in Hypertension Patients at High CV Risk by Robustly and Durably Lowering Blood Pressure – – Alnylam will Receive an Upfront Cash Payment of $310 Million and ...

press release

July 19, 2023

— Dose Dependent Reductions in Serum Angiotensinogen and 24 hour Ambulatory Blood Pressure Were Sustained for Six Months After Single Doses of Zilebesiran — — Acceptable Safety Profile Supporting Further Development — CAMBRIDGE, Mass. (BUSINESS WIRE) Jul. 19, 2023 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that results from its Phase 1 study ...

press release

May 4, 2023

− Achieved First Quarter 2023 Global Net Product Revenues of $276 Million, Representing 48% Year Over Year Growth Compared to Q1 2022 – − Reported Positive Interim Phase 1 Clinical Data on ALN APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy, Establishing First Ever Human Translation of RNAi Therapeutics in CNS – − Reiterated 2023 Financial Guidance, Including ...

news

April 24, 2023

For more than 20 years, Alnylam has been leading the way, advancing RNAi therapeutics as a whole new class of innovative medicines and this past year was no different. In fact, 2022 proved to be a banner year for Alnylam marked by significant milestones and steady progress on our journey toward achieving our 5 year vision, Alnylam P5x25. I invite ...